Compliance for Interventional Pain Management: A Practical Q&A

Interventional pain management carries a distinctive compliance risk profile because it combines three things regulators watch closely: high-volume procedures, controlled substances, and in-office ancillary services. That combination has drawn sustained OIG and payer attention, which means a pain practice's compliance program can't be generic — it has to address the exposures the specialty actually generates. This guide covers the ones that matter most.

A note on specifics: Regulatory requirements and coverage rules change and vary by jurisdiction. Treat this as a framework and confirm current obligations with qualified compliance and legal counsel and against active CMS and MAC guidance.

Compliance for Interventional Pain Management: A Practical Q&A

Compliance for Interventional Pain Management: A Practical Q&A

Q: What are the largest compliance exposures unique to interventional pain?

Four dominate. First, medical-necessity documentation measured against LCD requirements — frequency limits and conservative-care prerequisites for injections. Second, urine drug testing practices, which have generated significant enforcement where testing was excessive or protocol-driven rather than individualized. Third, opioid prescribing and monitoring, including PDMP use and treatment agreements. Fourth, financial-relationship rules — Stark and the Anti-Kickback Statute — around ancillary services, ASC ownership, and vendor arrangements. A program that covers general healthcare compliance but doesn't specifically address these four leaves the specialty's real risk uncovered.

Q: Why is urine drug testing such an enforcement flashpoint?

Because UDT is legitimately part of responsible opioid management, but it's also been the basis for major enforcement actions where practices ran blanket high-complexity confirmatory panels on every patient at every visit regardless of clinical indication, sometimes with a financial interest in the testing. The problem isn't testing — it's uniform, high-volume testing untethered from individual clinical need. Defensible UDT is individualized: the choice between presumptive and definitive testing made for a documented reason, frequency tied to each patient's risk stratification, and no financial incentive driving volume. If the ordering pattern is identical across a whole patient panel, expect scrutiny, and be able to show the clinical logic behind each test.

Q: How do Stark and the Anti-Kickback Statute apply in a pain practice?

Stark restricts a physician from referring designated health services to an entity with which the physician has a financial relationship unless an exception applies; it's a strict-liability civil statute, so intent doesn't matter. The Anti-Kickback Statute criminalizes remuneration intended to induce referrals for federally reimbursed items or services, and it does turn on intent. In interventional pain, these surface around in-office ancillary services, ASC and imaging ownership, arrangements with device and lab vendors, and medical-director or marketing payments. The protections are fair-market-value compensation, written and commercially reasonable arrangements, and structures that fit recognized exceptions and safe harbors. Informal, undocumented, or referral-tied arrangements are where liability lives.

Q: What LCD-driven medical-necessity rules cause the most compliance trouble?

Frequency limitations and step-therapy prerequisites for injections. Medicare contractors have tightened coverage for epidural steroid injections and facet interventions — commonly limiting injections per anatomic region per year and requiring documented conservative care plus quantified relief from prior injections before covering repeats. The compliance failure is running a fixed clinical cadence that outpaces what the LCD covers and then either absorbing denials or, worse, billing in ways that don't match the record. Aligning the treatment plan to the active LCD, and documenting the clinical justification when an exception is warranted, keeps utilization defensible.

Q: What does opioid-prescribing compliance require in this setting?

The core elements: checking the state prescription drug monitoring program before prescribing and at defined intervals, using controlled-substance treatment agreements, conducting and documenting risk assessments, prescribing consistent with clinical guidelines and any applicable state limits, and coordinating UDT with the prescribing plan. Documentation is the thread through all of it — the record should show why a controlled substance is indicated, what monitoring is in place, and how the practice responds to red flags. Opioid prescribing in a pain practice is both a clinical-quality and a compliance issue, and the two can't be separated.

Q: What should an interventional pain compliance program actually contain?

The seven elements the OIG has long described: written policies and a code of conduct; a designated compliance officer and committee; effective training and education; open lines of communication for reporting concerns; auditing and monitoring; enforcement through well-publicized disciplinary standards; and prompt response and corrective action when problems surface. For pain specifically, layer on controlled-substance protocols, a written UDT policy, and routine internal audits of high-risk codes, modifier usage, and documentation. The distinction that matters: a program that exists on paper but never audits anything provides very little protection when an external reviewer arrives.

Q: How often should a pain practice audit its own coding and documentation?

Routinely and by design, not reactively. A practical rhythm is periodic focused audits of the highest-volume and highest-risk codes — injections against LCD requirements, modifier 25 and 59 usage, UDT ordering patterns, and repeat-procedure documentation. The point of internal auditing is to find and fix the systematic error before it replicates across hundreds of claims or before an external audit finds it first. Documented self-auditing and corrective action also demonstrate a functioning compliance program, which matters if the practice ever has to show good faith.

What are the warning signs that a practice's utilization looks like an outlier?

What are  the warning signs that a practice's utilization looks like an outlier?

Volume and uniformity. Injection frequencies well above regional norms, UDT ordered identically across all patients, modifier 25 on nearly every procedure day, repeat procedures without documented interval relief, and multi-level or bilateral billing at rates that stand out against peers. Payers and the OIG use data analytics to flag exactly these patterns. Being an outlier isn't automatically wrongdoing, but it invites review, and the practice's protection is a documented clinical rationale for its patterns. If the volume can't be explained by the record, it's a liability.

Q: How does compliance interact with clinical documentation integrity?

They're inseparable in this specialty. The same documentation that supports good patient care — the specific pain generator, the conservative care tried, the response to prior interventions, the monitoring around controlled substances — is exactly what supports medical necessity and compliance. Clinical documentation integrity ensures the record accurately and completely reflects the care delivered, which simultaneously protects reimbursement and demonstrates compliance. Investing in documentation quality isn't a separate compliance cost; it's the foundation both the clinical and the regulatory case are built on.

Q: What's the single most cost-effective compliance investment for a pain practice?

A functioning internal audit-and-education loop. Regular focused audits of the specialty's high-risk areas, feeding directly into targeted education for the clinicians and coders, catches systematic problems early and creates the documented evidence of a working program. It's far cheaper than defending an external audit, repaying extrapolated overpayments, or managing an enforcement action. In a specialty where a single repeated error scales across high procedure volume and where regulators are actively watching, the audit loop is where compliance dollars do the most work.

Miss Pinky Maniri is a National Speaker and Global Healthcare Operations Strategist, a Founder and CEO, and a recognized authority in revenue cycle leadership, AI governance, clinical documentation integrity, and specialty practice operations. As the founder of GoHealthcare Practice Solutions, GoHealthcare AI Solutions, Axendra Solutions, and Vaydah Healthcare, she has built a multi enterprise ecosystem that shapes operational excellence across the United States and internationally. With more than twenty years of experience guiding medical practices, healthcare organizations, global nurse workforce pipelines, and physician enterprises, she is widely regarded as a leading voice in predictive intelligence, compliance strategy, and C suite healthcare transformation.

GoHealthcare Practice Solutions manages denials and appeals as part of full-service pain management prior authorization and revenue cycle management for interventional pain and spine practices. Call 1 (800) 267-8752 to stop leaving winnable denials on the table.
This article is for general educational purposes and is not legal or billing advice; verify current payer policies and appeal procedures before acting.